Table 3. Frequency of Major and Ancillary Features in Non-HCC Malignancies and HCC.
| Data Available | Non-HCC Malignancies (n = 58) (%) |
HCC (n = 616) (%) |
P * | ||
|---|---|---|---|---|---|
| Major features | |||||
| APHE | 674 | 18 (31.0) | 521 (84.5) | < 0.001 | |
| WO | 674 | 19 (32.7) | 489 (79.3) | < 0.001 | |
| Enhancing capsule | 674 | 5 (8.6) | 181 (29.4) | < 0.001 | |
| Threshold growth | 142 | 11/23 (47.8) | 17/119 (14.2) | < 0.001 | |
| Ancillary features | |||||
| Subthreshold growth | 53 | 5/7 (71.4) | 36/46 (78.3) | 0.704 | |
| Targetoid mass features | 674 | 32 (55.2) | 27 (4.4) | < 0.001 | |
| Corona enhancement | 674 | 22 (37.9) | 134 (21.8) | 0.005 | |
| Fat sparing in solid mass | 674 | 1 (1.7) | 13 (2.1) | 0.844 | |
| Restricted diffusion | 674 | 55 (94.8) | 585 (95.0) | 0.963 | |
| Mild to moderate T2 hyperintensity | 674 | 53 (91.4) | 579 (94.0) | 0.431 | |
| Iron sparing in solid mass | 674 | 0 (0) | 3 (0.5) | > 0.999 | |
| TP hypointensity | 674 | 47 (81.0) | 562 (91.2) | 0.012 | |
| HBP Hypointensity | 674 | 54 (93.1) | 574 (93.2) | 0.982 | |
| Nonenhancing capsule | 674 | 2 (3.4) | 27 (4.4) | > 0.999 | |
| Nodule-in-nodule | 674 | 0 (0) | 7 (1.1) | > 0.999 | |
| Mosaic architecture | 674 | 2 (3.4) | 50 (8.1) | 0.203 | |
| Fat-in-nodule | 674 | 2 (3.4) | 99 (16.1) | 0.010 | |
| Blood product | 674 | 2 (3.4) | 56 (9.1) | 0.217 | |
*χ2 test or Fisher's exact test. APHE = (nonrim) arterial phase hyperenhancement, HBP = hepatobiliary phase, HCC = hepatocellular carcinoma, TP = transitional phase, WO = washout